Captor Therapeutics ® Investor Relations

      Investor Relations

      The Company purchased specialized laboratory equipment

      Publication date: 2021-09-29
      Number: RB ESPI 28/2021

      Current Report No. 28/2021

      Date of preparation: 29 September 2021

      Subject: The Company purchased specialized laboratory equipment

      Legal basis: Article 17(1) of the MAR Regulation - inside information

      The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław ("the Company"), informs that on 29 September 2021, the Company has entered into an agreement under which the Company purchased specialized laboratory equipment (including Orbitrap Exploris 480 mass spectrometer) intended for the Company's projects for a price of approximately PLN 4,170,000.00 net.

      The agreement was concluded with a Polish representative of renowned manufacturers of scientific and research apparatus and laboratory equipment. The delivery will consist of the LC-MS/MS system dedicated for high-throughput proteomic analysis together with appropriate bioinformatic software. The contract also provides for specialistic training for the system’s operators.

      The purchased equipment is state-of-the-art platform for qualitative and quantitative analysis of proteins and will be utilized in the newly established proteomic facility. Such facility is created in response to the Company’s growing demand towards research and development of the novel therapeutics, in particular in preclinical studies. The new equipment will accelerate the proteomic analyses as well as it will expand the breadth of experimental design. Whole proteome studies have become one of the most important tools to assess the mechanism of action of small molecule degraders. The proteomic analyses will be utilized by the majority of the Company’s ongoing and future research projects.

      The Company classified the agreement as material due to the value of the Company's consideration (price).